QurAlis to Present Data That Show its Splice-Switching ASOs Restore UNC13A Function in ALS and Frontotemporal Dementia
SV investment has resulted in the approval of 24 novel therapeutics
SV Health Investors bolsters senior biotech team - appoints Nikola Trbovic as Managing Partner and hires Jamil Beg as Partner
Hightop Health adds industry veteran to Board of Directors - Seasoned CEO and McLean Hospital Board Chair joins Hightop’s executive leadership
Merck to Acquire Caraway Therapeutics, Inc.
EyeBio Announces Expansion of Series A to $130 Million, Advances Development of Restoret for Retinal Diseases
SV Health Investors partners with HIT Executives Dave Dyell and Marc Hirshfield to Lead Recapitalization of Innovative Consulting Group
- 8 February 2022Portfolio NewsNordic named Best in KLAS for Overall IT Services, recognized for its industry-leading Advisory Services
- 8 February 2022Portfolio NewsLeiters Announces Facility Acquisition to Increase Capacity, Accommodate Growth and Expand Portfolio
- 25 January 2022Portfolio NewsLoQus23 Therapeutics appoints Dr. Melanie Ivarsson, OBE, as Non-Executive Director
- 6 January 2022Portfolio NewsSV Created TRexBio Announces Collaboration with Janssen to Discover Novel Targets for Immunology and Inflammation
- 5 January 2022Portfolio NewsEndotronix Announces FDA Approval for PROACTIVE-HF Pivotal Trial Design Change to Single-Arm Study
- 4 January 2022Portfolio NewsCarePredict, Inc. is mentioned in The Wall Street Journal as a top trend to watch in CES2022
- 14 December 2021Portfolio NewsZerigo Health Expands Board of Directors
- 8 December 2021Portfolio NewsCentauri Health Solutions Adds Clinical Data Exchange Capabilities with Acquisition of Secure Exchange Solutions
- 5 December 2021SV NewsKate Bingham FT op-ed: Covid has given UK biotech a lesson — and a legacy
- 1 December 2021Portfolio NewsAviadoBioTM Raises $80 million in Series A Financing to Advance Neurodegenerative Gene Therapy Platform
- 29 November 2021Portfolio NewsQuell Therapeutics Raises $156 million in Oversubscribed Series B Financing to Advance its Pioneering Multi-Modular Engineered T Regulatory (Treg) Cell Therapy Pipeline and Platform
- 23 November 2021Portfolio NewsLoQus23 Therapeutics exits stealth with £11.5 million seed financing from the Dementia Discovery Fund and Novartis Venture Fund